{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:03:58Z","timestamp":1771844638285,"version":"3.50.1"},"reference-count":39,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1136\/ejhpharm-2024-004372","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T18:40:18Z","timestamp":1750012818000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Nine years\u2019 experience of an educational programme for patients treated with oral anticoagulants in a cardiology department"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2963-2127","authenticated-orcid":false,"given":"Elisabeth","family":"Leclerc","sequence":"first","affiliation":[{"name":"Pharmacie \u00e0 Usage Int\u00e9rieur (PUI), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, AP-HP, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Cavagna","sequence":"additional","affiliation":[{"name":"Pharmacie \u00e0 Usage Int\u00e9rieur (PUI), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, AP-HP, Paris, \u00cele-de-France, France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, PARCC, F-75015 Paris, France, Team integrative epidemiology of cardiovascular diseases, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Cuquel","sequence":"additional","affiliation":[{"name":"Pharmacie \u00e0 Usage Int\u00e9rieur (PUI), H\u00f4pital Saint-Antoine, AP-HP, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Chung","sequence":"additional","affiliation":[{"name":"Pharmacie \u00e0 Usage Int\u00e9rieur (PUI), H\u00f4pital Saint-Antoine, AP-HP, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Pharmacie \u00e0 Usage Int\u00e9rieur (PUI), H\u00f4pital Saint-Antoine, AP-HP, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Lastennet","sequence":"additional","affiliation":[{"name":"Pharmacie \u00e0 Usage Int\u00e9rieur (PUI), H\u00f4pital Saint-Antoine, AP-HP, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Pharmacie \u00e0 Usage Int\u00e9rieur (PUI), H\u00f4pital Saint-Antoine, AP-HP, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Brito","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Antoine Service Cardiologie, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Cohen","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Antoine Service Cardiologie, Paris, \u00cele-de-France, France"},{"name":"Unit\u00e9 INSERM UMRS 1166 Unit\u00e9 de recherche sur les maladies cardiovasculaires et m\u00e9taboliques, Institut Hospitalo-Universitaire, Institut de Cardiom\u00e9tabolisme et Nutrition (ICAN), Sorbonne Universit\u00e9, F-75013, Paris, France, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Antignac","sequence":"additional","affiliation":[{"name":"Pharmacie \u00e0 Usage Int\u00e9rieur (PUI), Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, AP-HP, Paris, \u00cele-de-France, France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, PARCC, F-75015 Paris, France, Team integrative epidemiology of cardiovascular diseases, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"2026022302200639000_33.2.117.1","unstructured":"ANSM Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 . Rapport - les anticoagulants en france en 2012: \u00e9tat des lieux et surveillance. Juillet; 2012. Available: https:\/\/ansm.sante.fr\/uploads\/2021\/03\/12\/901e9c291a545dff52c0b41365c0d6e2.pdf"},{"key":"2026022302200639000_33.2.117.2","unstructured":"Arr\u00eat\u00e9 du 6 avril 2011 relatif au management de la qualit\u00e9 de la prise en charge m\u00e9dicamenteuse et aux m\u00e9dicaments dans les \u00e9tablissements de sant\u00e9. Legifrance; 2011. Available: https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000023865866\/"},{"key":"2026022302200639000_33.2.117.3","unstructured":"Clinical Excellence Commission (New South Wales Government) . High risk medicine standard: anticoagulants. 2024. Available: https:\/\/www.cec.health.nsw.gov.au\/__data\/assets\/pdf_file\/0011\/933689\/Printable-HRM-Standard-Anticoagulants.PDF"},{"key":"2026022302200639000_33.2.117.4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.therap.2017.05.004","article-title":"Misuse and adverse effects of new direct oral anticoagulants: a prospective observational study in patients admitted to an emergency unit of a French university hospital","volume":"73","author":"Lafon","year":"2018","journal-title":"Therapie"},{"key":"2026022302200639000_33.2.117.5","unstructured":"HAS Haute Autorit\u00e9 de Sant\u00e9 . Les anticoagulants oraux, 2018. Available: https:\/\/www.has-sante.fr\/jcms\/c_2851086\/fr\/les-anticoagulants-oraux"},{"key":"2026022302200639000_33.2.117.6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10840-023-01585-x","article-title":"Lower-adherence direct oral anticoagulant use is associated with increased risk of thromboembolic events than warfarin","volume":"67","author":"Bawa","year":"2024","journal-title":"J Interv Card Electrophysiol"},{"key":"2026022302200639000_33.2.117.7","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euz273"},{"key":"2026022302200639000_33.2.117.8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-9-200011070-00010"},{"key":"2026022302200639000_33.2.117.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0690-1"},{"key":"2026022302200639000_33.2.117.10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0398-0499(04)96736-4","article-title":"\u00c9ducation th\u00e9rapeutique des patients sous anticoagulants oraux pour maladie thromboembolique veineuse: description du programme Educ\u2019AVK. Therapeutic education of patients receiving anticoagulants for thromboembolic venous disease: description of the Educ\u2019AVK program","volume":"29","author":"L\u00e9ger","year":"2004","journal-title":"J Mal Vasc"},{"key":"2026022302200639000_33.2.117.11","unstructured":"ANSM Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 . Etude Nouveaux AntiCOagulants et Risques Associ\u00e9s-Switch Etude NACORA-Switch; Etude - Etude des risques h\u00e9morragiques et thromboemboliques art\u00e9riels li\u00e9s au changement de traitement d\u2019un m\u00e9dicament antivitamine K (AVK) vers un anticoagulant oral direct (AOD) chez les individus n\u00e9cessitant une anticoagulation \u00e0 long-terme en conditions r\u00e9elles d\u2019utilisation, 2014. Available: https:\/\/archive.ansm.sante.fr\/content\/download\/64711\/828903\/version\/4\/file\/NACORA+-etude+ANSMjuillet2014.pdf"},{"key":"2026022302200639000_33.2.117.12","unstructured":"CNAM Caisse Nationale de l\u2019Assurance Maladie . Rapport nacora-br \u2013 etude \u00ab\u202fen vie r\u00e9elle\u202f\u00bb du b\u00e9n\u00e9fice\/risque \u00e0 court terme des nouveaux anticoagulants oraux (dabigatran, rivaroxaban) chez les patients d\u00e9butant un traitement et non pr\u00e9c\u00e9demment trait\u00e9s par des antivitamines k. Available: https:\/\/www.snds.gouv.fr\/download\/Epidemio\/NACORA_CNAMTSjuillet2014.pdf"},{"key":"2026022302200639000_33.2.117.13","unstructured":"Point sur l\u2019utilisation des nouveaux anticoagulants oraux, Available: https:\/\/www.has-sante.fr\/jcms\/c_1700943\/fr\/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux"},{"key":"2026022302200639000_33.2.117.14","unstructured":"Guide \u2013 ALD 5: Fibrillation auriculaire, Available: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/liste_ald_5_fibrillation_auriculaire.pdf"},{"key":"2026022302200639000_33.2.117.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"2026022302200639000_33.2.117.16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s11096-017-0475-x","article-title":"Impact of clinical pharmacist intervention in anticoagulation clinic in Sudan","volume":"39","author":"Ahmed","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"2026022302200639000_33.2.117.17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s11096-018-0691-z","article-title":"Pharmacist\u2019s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial","volume":"40","author":"Falami\u0107","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"2026022302200639000_33.2.117.18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01052","article-title":"Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin","volume":"9","author":"Marcatto","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026022302200639000_33.2.117.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146927","article-title":"Discrepancies between Patients\u2019 Preferences and Educational Programs on Oral Anticoagulant Therapy: A Survey in Community Pharmacies and Hospital Consultations","volume":"11","author":"Macquart de Terline","year":"2016","journal-title":"PLoS ONE"},{"key":"2026022302200639000_33.2.117.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00634.x"},{"key":"2026022302200639000_33.2.117.21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1611179","article-title":"Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes","volume":"377","author":"Berlowitz","year":"2017","journal-title":"N Engl J Med"},{"key":"2026022302200639000_33.2.117.22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMsa1616035","article-title":"Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control","volume":"377","author":"Bress","year":"2017","journal-title":"N Engl J Med"},{"key":"2026022302200639000_33.2.117.23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11096-020-00964-y","article-title":"Evaluation of a program of pharmaceutical counseling for French patients on oral anticoagulant therapy","volume":"42","author":"Roseau","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"2026022302200639000_33.2.117.24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjh.14134","article-title":"Adherence to long-term anticoagulation treatment, what is known and what the future might hold","volume":"174","author":"Abdou","year":"2016","journal-title":"Br J Haematol"},{"key":"2026022302200639000_33.2.117.25","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv448"},{"key":"2026022302200639000_33.2.117.26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FJC.0000000000000558","article-title":"Factors Influencing Various Aspects of Patients\u2019 Knowledge of Oral Anticoagulation","volume":"71","author":"Pourafkari","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026022302200639000_33.2.117.27","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s11096-017-0544-1","article-title":"Patients\u2019 knowledge on oral anticoagulant treatment in Hungary","volume":"39","author":"Viola","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"2026022302200639000_33.2.117.28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pharma.2014.02.004","article-title":"\u00c9valuation de l\u2019impact d\u2019un programme de formation aux antagonistes de la vitamine K (AVK) pour les \u00e9tudiants en pharmacie sur l\u2019am\u00e9lioration des connaissances des patients trait\u00e9s par AVK pris en charge au cours de leur stage clinique hospitalier [Evaluation of the impact of a training program on vitamin K antagonists (VKA) implemented by pharmacy students aiming at improving the knowledge of patients receiving vitamin K antagonists during their hospital clinical training course]","volume":"72","author":"Conort","year":"2014","journal-title":"Ann Pharm Fr"},{"key":"2026022302200639000_33.2.117.29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lpm.2012.12.002","article-title":"L\u2019\u00e9ducation th\u00e9rapeutique en g\u00e9riatrie : quelles sp\u00e9cificit\u00e9s ?","volume":"42","author":"Pariel","year":"2013","journal-title":"Presse Med"},{"key":"2026022302200639000_33.2.117.30","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619847423","article-title":"Patient-focused interventions to support vulnerable people using oral anticoagulants: a narrative review","volume":"10","author":"Yiu","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"2026022302200639000_33.2.117.31","doi-asserted-by":"crossref","first-page":"2333721416672970","DOI":"10.1177\/2333721416672970","article-title":"Feasibility Study of a Mobile Health Intervention for Older Adults on Oral Anticoagulation Therapy","volume":"2","author":"Lee","year":"2016","journal-title":"Gerontol Geriatr Med"},{"key":"2026022302200639000_33.2.117.32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ijpp.12584","article-title":"Impact of a pharmacist-led education and follow-up service on anticoagulation control and safety outcomes at a tertiary hospital in China: a randomised controlled trial","volume":"28","author":"Liang","year":"2020","journal-title":"Int J Pharm Pract"},{"key":"2026022302200639000_33.2.117.33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.12669\/pjms.342.14216","article-title":"Effects of structured patient education on knowledge level and INR control of patients receiving warfarin: randomized controlled trial","volume":"34","author":"Baysal","year":"2018","journal-title":"Pak J Med Sci"},{"key":"2026022302200639000_33.2.117.34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2021.03.003","article-title":"Patients\u2019 adherence to oral anticoagulants therapy: comparison between vitamin K antagonists and direct oral anticoagulants","volume":"333","author":"Barcellona","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026022302200639000_33.2.117.35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.thromres.2015.07.007","article-title":"Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale","volume":"136","author":"Castellucci","year":"2015","journal-title":"Thromb Res"},{"key":"2026022302200639000_33.2.117.36","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/217047","article-title":"Medication Adherence Measures: An Overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int"},{"key":"2026022302200639000_33.2.117.37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15386\/mpr-1201","article-title":"An overview of the common methods used to measure treatment adherence","volume":"92","author":"Anghel","year":"2019","journal-title":"Med Pharm Rep"},{"key":"2026022302200639000_33.2.117.38","unstructured":"D\u00e9cret n\u00b0 2017\u2013884 du 9 mai 2017 modifiant certaines dispositions r\u00e9glementaires relatives aux recherches impliquant la personne humaine. Legifrance; 2017. Available: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000034634217"},{"key":"2026022302200639000_33.2.117.39","unstructured":"Loi n\u00b0 2004-801 du 6 ao\u00fbt 2004 relative \u00e0 la protection des personnes physiques \u00e0 l\u2019\u00e9gard des traitements de donn\u00e9es \u00e0 caract\u00e8re personnel et modifiant la loi n\u00b0 78-17 du 6 janvier 1978 relative \u00e0 l\u2019informatique, Available: https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000000441676"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:21:01Z","timestamp":1771842061000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/ejhpharm-2024-004372"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004372","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]}}}